
Shijie Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6024428/publications.pdf Version: 2024-02-01



Sumeli

#	Article	IF	CITATIONS
1	Targeting mutant p53 for cancer therapy: direct and indirect strategies. Journal of Hematology and Oncology, 2021, 14, 157.	17.0	190
2	Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. Journal of Hematology and Oncology, 2020, 13, 118.	17.0	95
3	Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 38-51.	7.7	58
4	Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transduction and Targeted Therapy, 2020, 5, 241.	17.1	51
5	An integrated electrochemical POCT platform for ultrasensitive circRNA detection towards hepatocellular carcinoma diagnosis. Biosensors and Bioelectronics, 2021, 192, 113500.	10.1	26
6	Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era. International Journal of Cancer, 2020, 147, 1778-1792.	5.1	21
7	Development and Validation of a Nomogram for Predicting Survival in Gallbladder Cancer Patients With Recurrence After Surgery. Frontiers in Oncology, 2020, 10, 537789.	2.8	11
8	Bortezomibâ€Encapsulated Dual Responsive Copolymeric Nanoparticles for Gallbladder Cancer Targeted Therapy. Advanced Science, 2022, 9, e2103895.	11.2	11
9	Hepatectomy strategy for T2 gallbladder cancer between segment IVb and V resection and wedge resection: A propensity score-matched study. Surgery, 2021, 169, 1304-1311.	1.9	10
10	Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 302-310.	2.8	7
11	Identification of invasion-metastasis associated MiRNAs in gallbladder cancer by bioinformatics and experimental validation. Journal of Translational Medicine, 2022, 20, 188.	4.4	7
12	Comparison of Outcomes After Primary Laparoscopic Versus Open Approach for T1b/T2 Gallbladder Cancer. Frontiers in Oncology, 2021, 11, 758319.	2.8	6
13	DNA damage response inhibitionâ€based combination therapies in cancer treatment: Recent advances and future directions. Aging and Cancer, 2022, 3, 44-67.	1.6	2
14	Enhanced Recovery Care vs. Traditional Care in Laparoscopic Hepatectomy: A Systematic Review and Meta-Analysis. Frontiers in Surgery, 2022, 9, 850844.	1.4	2
15	Nephroscopic Management of Giant Infected Pancreatic Pseudocyst After Drainage. Indian Journal of Surgery, 2021, 83, 754-757.	0.3	1